Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis

被引:259
作者
Schwab, M
Schaeffeler, E
Marx, C
Fromm, MF
Kaskas, B
Metzler, J
Stange, E
Herfarth, H
Schoelmerich, J
Gregor, M
Walker, S
Cascorbi, I
Roots, I
Brinkmann, U
Zanger, UM
Eichelbaum, M
机构
[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany
[2] Univ Tubingen Hosp, Dept Gastroenterol, Tubingen, Germany
[3] Robert Bosch Krankenhaus, Dept Gastroenterol, Stuttgart, Germany
[4] Univ Hosp Regensburg, Dept Gastroenterol, Regensburg, Germany
[5] Ernst Moritz Arndt Univ Greifswald, Inst Pharmacol, Greifswald, Germany
[6] Humboldt Univ, Med Ctr, Inst Clin Pharmacol, Berlin, Germany
[7] Epidauros Biotechnol AG, Bernried, Germany
[8] Univ Tubingen Hosp, Div Clin Pharmacol, Tubingen, Germany
关键词
D O I
10.1053/gast.2003.50010
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: The human multidrug resistance 1 (MDR1) gene product P-glycoprotein is highly expressed in intestinal epithelial cells, where it constitutes a barrier against xenobiotics. The finding that mdr1a knockout mice develop a form of colitis that is similar to ulcerative colitis, which can be prevented by antibiotics, indicates a barrier function for P-glycoprotein against the invasion of bacteria or toxins. Because the MDR1 single nucleotide polymorphism C3435T is associated with lower intestinal P-glycoprotein expression, we tested whether this polymorphism predisposes to development of ulcerative colitis. Methods: Allele frequencies and genotype distributions of the C3435T single nucleotide polymorphism were investigated in 149 patients with ulcerative colitis, 126 patients with Crohn's disease, and sex-matched healthy controls. Results: Significantly increased frequencies of the 3435T allele and the 3435TT genotype were observed in patients with ulcerative colitis compared with controls (3435T: P = 0.049; odds ratio, 1.4; 95% confidence interval, 1.02-1.94; 3435TT: P = 0.045; odds ratio, 2.03; 95% confidence interval, 1.04-3.95). In contrast, frequencies of the T allele and the TT genotype were the same in patients with Crohn's disease as in controls (P = 0.66 and P = 0.59, respectively). In comparison to 998 non-sex-matched controls, the effect for the TT genotype in ulcerative colitis patients was more pronounced (P = 0.0055; odds ratio, 2.1). Conclusions: The higher frequency of the 3435TT genotype in patients with ulcerative colitis corroborates the findings from the mdr1a knockout mice. The results support the notion that P-glycoprotein plays a major role in the defense against intestinal bacteria or toxins. Impairment of barrier function in 3435TT subjects could render this genotype more susceptible to the development of ulcerative colitis.
引用
收藏
页码:26 / 33
页数:8
相关论文
共 50 条
[1]   Biochemical, cellular, and pharmacological aspects of the multidrug transporter [J].
Ambudkar, SV ;
Dey, S ;
Hrycyna, CA ;
Ramachandra, M ;
Pastan, I ;
Gottesman, MM .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1999, 39 :361-398
[2]   MDR1 pharmacogenetics:: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity [J].
Ameyaw, MM ;
Regateiro, F ;
Li, T ;
Liu, XH ;
Tariq, M ;
Mobarek, A ;
Thornton, N ;
Folayan, GO ;
Githang'a, J ;
Indalo, A ;
Ofori-Adjei, D ;
Price-Evans, DA ;
McLeod, HL .
PHARMACOGENETICS, 2001, 11 (03) :217-221
[3]   Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects [J].
Cascorbi, I ;
Gerloff, T ;
Johne, A ;
Meisel, C ;
Hoffmeyer, S ;
Schwab, M ;
Schaeffeler, E ;
Eichelbaum, M ;
Brinkmann, U ;
Roots, I .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :169-174
[4]   Identification of cdtB homologues and cytolethal distending toxin activity in enterohepatic Helicobacter spp. [J].
Chien, CC ;
Taylor, NS ;
Ge, ZM ;
Schauer, DB ;
Young, VB ;
Fox, JG .
JOURNAL OF MEDICAL MICROBIOLOGY, 2000, 49 (06) :525-534
[5]   EXPRESSION OF THE MULTIDRUG RESISTANCE GENE-PRODUCT (P-GLYCOPROTEIN) IN HUMAN NORMAL AND TUMOR-TISSUES [J].
CORDONCARDO, C ;
OBRIEN, JP ;
BOCCIA, J ;
CASALS, D ;
BERTINO, JR ;
MELAMED, MR .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1990, 38 (09) :1277-1287
[6]   The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease [J].
Cuthbert, AP ;
Fisher, SA ;
Mirza, MM ;
King, K ;
Hampe, J ;
Croucher, PJP ;
Mascheretti, S ;
Sanderson, J ;
Forbes, A ;
Mansfield, J ;
Schreiber, S ;
Lewis, CM ;
Mathew, CG .
GASTROENTEROLOGY, 2002, 122 (04) :867-874
[7]   The gut's role in metabolism, mucosal barrier function, and gut immunology [J].
DeWitt, RC ;
Kudsk, KA .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 1999, 13 (02) :465-+
[8]   MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine [J].
Drescher, S ;
Schaeffeler, E ;
Hitzl, M ;
Hofmann, U ;
Schwab, M ;
Brinkmann, U ;
Eichelbaum, M ;
Fromm, MF .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (05) :526-534
[9]   Ulcerative colitis [J].
Farrell, RJ ;
Peppercorn, MA .
LANCET, 2002, 359 (9303) :331-340
[10]   High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy [J].
Farrell, RJ ;
Murphy, A ;
Long, A ;
Donnelly, S ;
Cherikuri, A ;
O'Toole, D ;
Mahmud, N ;
Keeling, PWN ;
Weir, DG ;
Kelleher, D .
GASTROENTEROLOGY, 2000, 118 (02) :279-288